Rosemarie Tully
Corporate Officer/Principal chez The Pharmaceutical Society of Ireland
Profil
Rosemarie Tully is a Member at The Pharmaceutical Society of Ireland, and has previously worked as a Senior Director-Corporate Development at Elan Corp.
Plc, Chief Business Officer at Sublimity Therapeutics Ltd., and Chief Operating Officer at Neuromod Devices Ltd.
She holds an MBA from INSEAD and an undergraduate degree from Trinity College Dublin.
Postes actifs de Rosemarie Tully
| Sociétés | Poste | Début |
|---|---|---|
| The Pharmaceutical Society of Ireland | Corporate Officer/Principal | - |
Anciens postes connus de Rosemarie Tully
| Sociétés | Poste | Fin |
|---|---|---|
Neuromod Devices Ltd.
 Neuromod Devices Ltd. Medical SpecialtiesHealth Technology Neuromod Devices Ltd. operates as a medical device company which engages in the research and development of neuromodulation technologies for chronic tinnitus. The firm develops proprietary neuromodulation technologies designed to address pathologies, which are believed to give rise to illusory perceptions, such as tinnitus. These technologies utilize bi-modal neuromodulation and aim to promote positive therapeutic change within the human nervous system. The company was founded by Ross O?Neill in 2010 and is headquartered in Dublin, Ireland. | Directeur des opérations | 30/08/2021 |
Elan Corp. Plc
 Elan Corp. Plc Pharmaceuticals: MajorHealth Technology Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland. | Corporate Officer/Principal | - |
Sublimity Therapeutics Ltd.
 Sublimity Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Sublimity Therapeutics Ltd. develops and manufactures pharmaceutical products. It engages in the development of gastrointestinal and immunological therapeutics. The firm’s lead product, CyCol, harnesses the powerful efficacy of the known immunosuppressive drug, cyclosporine in a safer format by targeting drug release towards the site of diseased tissue in the colon of patients with ulcerative colitis. Its other products include CyCron, AlloCol, CyLow, oral vaccines and oral peptides. The company was founded by Ivan Coulter in 2003 and is headquartered in Dublin, Ireland. | Corporate Officer/Principal | - |
Formation de Rosemarie Tully
| Trinity College Dublin | Undergraduate Degree |
| INSEAD | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Sublimity Therapeutics Ltd.
Sublimity Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Sublimity Therapeutics Ltd. develops and manufactures pharmaceutical products. It engages in the development of gastrointestinal and immunological therapeutics. The firm’s lead product, CyCol, harnesses the powerful efficacy of the known immunosuppressive drug, cyclosporine in a safer format by targeting drug release towards the site of diseased tissue in the colon of patients with ulcerative colitis. Its other products include CyCron, AlloCol, CyLow, oral vaccines and oral peptides. The company was founded by Ivan Coulter in 2003 and is headquartered in Dublin, Ireland. | Health Technology |
Elan Corp. Plc
Elan Corp. Plc Pharmaceuticals: MajorHealth Technology Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland. | Health Technology |
| The Pharmaceutical Society of Ireland | |
Neuromod Devices Ltd.
Neuromod Devices Ltd. Medical SpecialtiesHealth Technology Neuromod Devices Ltd. operates as a medical device company which engages in the research and development of neuromodulation technologies for chronic tinnitus. The firm develops proprietary neuromodulation technologies designed to address pathologies, which are believed to give rise to illusory perceptions, such as tinnitus. These technologies utilize bi-modal neuromodulation and aim to promote positive therapeutic change within the human nervous system. The company was founded by Ross O?Neill in 2010 and is headquartered in Dublin, Ireland. | Health Technology |
